Supply
LEQEMBI injection is a preservative-free, sterile, clear to opalescent, and colorless to pale yellow solution. LEQEMBI is supplied via single-dose vials (per carton) or single-dose prefilled autoinjectors, as follows1:
200 mg/2 mL (100 mg/mL)
Single-dose vial with dark grey flip cap
NDC 62856-212-01
500 mg/5 mL (100 mg/mL)
Single-dose vial with white flip cap
NDC 62856-215-01
360 mg/1.8 mL (200 mg/mL)
-
Single-dose prefilled autoinjector
NDC 62856-220-01
To reorder LEQEMBI, contact your
specialty distributor or specialty pharmacy
Storage and handling1
Diluted solution (Infusion)
After dilution, immediate use is recommended
If not administered immediately, store LEQEMBI refrigerated at 2°C to 8°C (36°F to 46°F) for up to 4 hours, or at room temperature up to 30°C (86°F) for up to 4 hours. Do not freeze
Unopened vial (Infusion)
Store in refrigerator at 2°C to 8°C (36°F to 46°F)
Store in the original carton to protect from light
Do not freeze or shake
Subcutaneous Injection
-
Refrigerate autoinjectors at 2°C to 8°C (36°F to 46°F)
-
Do not freeze
-
Store in original carton to protect from light
-
Once removed from the refrigerator, the autoinjector can be stored in the carton up to 14 days at room temperature 25°C (77°F). Once LEQEMBI® IQLIK™ has reached room temperature, do not return to the refrigerator
-
If these conditions are exceeded, LEQEMBI IQLIK must be discarded
Use in specific populations1
There are no adequate data on
LEQEMBI use in pregnant women,
women who are breastfeeding, or
pediatric patients.
For the geriatric population, in Study 1 and Study 2, the age of patients exposed to LEQEMBI 10 mg/kg every 2 weeks ranged from 50 to 90 years, with a mean age of 72 years; 81% were 65 years and older, and 39% were 75 years and older. No overall differences in safety or effectiveness of LEQEMBI have been observed between patients 65 years of age and older and younger adult patients.
